Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Dexcom (DXCM – Research Report) yesterday and set a price target of ...
Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Dexcom (DXCM – Research Report) on September 13 and set a price target of ...
Ithaka US Growth Strategy highlighted stocks like DexCom, Inc. (NASDAQ:DXCM), in the second quarter 2024 investor letter. DexCom, Inc. (NASDAQ:DXCM) is a medical device company engages in the ...
Medical device specialist DexCom (NASDAQ: DXCM) is going through a rough patch. The company's shares dropped off a cliff following its second-quarter earnings report. However, zooming out helps ...
DexCom is one of the leaders in an industry with massive growth potential. The company is building a competitive advantage. Despite several risks, it could deliver substantial returns in the long ...
San Diego’s Dexcom began sales this week of Stelo, the industry’s first FDA-approved continuous glucose monitor that doesn’t require a prescription. With a two-pack of the biosensor costing ...
A tiny streaming box tapping into the power of Android, the Fetch Mini Gen 5 (G5) puts the best of broadcast and internet video at your fingertips. For Australians who don’t want to hand over their ...
We first reported on Stelo at CES 2024, and 8 months on, it’s now available in the US without a prescription. Unlike the company’s existing G7 CGM, Stelo is designed for adults 18+ who are not ...
Stelo is a small biosensor worn on the back of the upper arm that leverages Dexcom's most accurate glucose sensing technology. 5 It is specifically designed to provide the 125 million Americans 6 with ...
Aug 26 (Reuters) - Dexcom (DXCM.O), opens new tab said on Monday its over-the-counter continuous glucose monitor, Stelo, is now available for use in the United States at a price of up to $99.
Instead, I’ve been checking my glucose levels. That’s because on the underside of my left arm is a Dexcom Stelo continuous glucose monitor (CGM). Some days, I’m relieved by what I see.